Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy

Trial Profile

Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2012

At a glance

  • Drugs Bevacizumab (Primary) ; Exemestane
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2012 Actual initiation date (10 Mar 2011) added as reported by European Clinical Trials Database record.
    • 28 Mar 2012 Planned end date (10 Sep 2014) added as reported by European Clinical Trials Database record.
    • 25 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top